Meanwhile, Carmot\u2019s oral GLP-1 CT-996, which posted some promising early-stage clinical results<\/a> in 2024, began a phase 2 study this year, according to the presentation<\/a>.<\/p>\n Roche further cemented its weight loss ambitions in March via a $1.6 billion upfront deal<\/a>\u00a0to codevelop and co-commercialize Zealand Pharma\u2019s long-acting amylin analog petrelintide. But the company had not outlined a cohesive strategy for its various obesity assets\u2014until today.<\/p>\n \u201cI know many of you have been waiting for this,\u201d Graham acknowledged to investors at this morning\u2019s event.<\/p>\n \u201cTo sum it up, our capabilities strongly position us to deliver here,\u201d Graham continued. \u201cFrom multiple pipeline assets of best-in-class and best-in-disease potential, the ability to leverage synergies across the portfolio, our global robust manufacturing network, our presence in more than 150 countries with our global commercial footprint and, of course, our very unique ability to leverage our pharma-dia[gnostics] connection, we believe that those capabilities, in total, executed correctly, will allow us to become a top three player in obesity.\u201d<\/p>\n \u201cWe are committed to making that happen,\u201d she added.<\/p>\n The company is eyeing peak sales of more than $3 billion for both CT-388 and petrelintide, according to Roche\u2019s presentation.<\/p>\n <\/a><\/p>\n Roche obesity slide<\/p>\n The idea is that combining assets across Roche\u2019s wider portfolio could help differentiate the pharma\u2019s offering. For example, combining CT-388 with petrelintide could address nausea, which is the main driver of discontinuation from existing weight loss products. The acquisition of 89bio<\/a> last week also adds the possibility of using the biotech\u2019s phase 3-stage fatty liver disease drug pegozafermin to address some of the comorbidities of obesity.<\/p>\n The difficulties with securing and maintaining a top spot in obesity become apparent in recent months, with Novo Nordisk launching a\u00a0major restructure<\/a>\u00a0in the wake of\u00a0underwhelming data<\/a>\u00a0for its next-gen obesity portfolio, while Pfizer\u00a0almost abandoned<\/a>\u00a0the field completely.<\/p>\n
\n <\/p>\n